Aldosterone

Overview

A hormone secreted by the adrenal cortex that regulates electrolyte and water balance by increasing the renal retention of sodium and the excretion of potassium.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Investigating Salt Taste Threshold in Patients Being Investigated for Primary Hyperaldosteronism Before and After Treatment.	2020/09/21	NCT04556279	N/A	Withdrawn	Imperial College London
Non Invasive Assessment of Heart Failure	2019/09/06	NCT04078425	Early Phase 1	UNKNOWN	Assiut University
Controlling Blood Pressure in Treatment Resistant Hypertension: A Pilot Study	2014/06/19	NCT02167464	Not Applicable	Completed	Medical University of South Carolina
Aldosterone and Glucose Homeostasis	2008/08/11	NCT00732160	Not Applicable	Completed	Vanderbilt University
Studies on Aldosterone and Vascular Function	2008/06/18	NCT00700479	Phase 1	Completed	Yale University
Curing Atrial Fibrillation in Heart Failure	2006/02/15	NCT00292162	Not Applicable	Completed	NHS Greater Glasgow and Clyde

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
Hormone Balance	Dr. Donna Restivo DC	62185-0050	ORAL	12 [hp_C] in 1 mL	5/23/2025

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

ACHIEVE Trial Shows Spironolactone Fails to Reduce Cardiovascular Risk in Dialysis Patients

3 months ago

The ACHIEVE trial, the largest study to date with 2,538 dialysis patients across 12 countries, found that spironolactone did not significantly reduce cardiovascular death or heart failure hospitalization compared to placebo.

Researchers Challenge Standard Diagnostic Test for Primary Aldosteronism, Call for Paradigm Shift in Hypertension Care

4 months ago

A new study published in Annals of Internal Medicine found that the seated saline suppression test (SSST) commonly used to confirm primary aldosteronism is often inaccurate and may prevent patients from receiving effective treatment.

Novel Drug Lorundrostat Shows Significant Promise for Uncontrolled Hypertension in Phase 2b Trial

5 months ago

Cleveland Clinic-led clinical trial demonstrates lorundrostat, an aldosterone synthase inhibitor, reduced systolic blood pressure by 8 points more than placebo in patients with uncontrolled hypertension.

Mineralys Therapeutics Secures $175 Million in Public Offering to Advance Aldosterone Inhibitor for Cardiorenal Diseases

6 months ago

Mineralys Therapeutics has priced its public offering at $13.50 per share, raising approximately $175 million to fund the clinical development of lorundrostat, its aldosterone synthase inhibitor.

Novel Minimally Invasive 'Triple T' Therapy Shows Promise in Treating Primary Aldosteronism

7 months ago

• UK researchers have developed Triple T (Targeted Thermal Therapy), a groundbreaking 20-minute minimally invasive procedure that treats primary aldosteronism without removing the adrenal gland. • The FABULAS trial demonstrated Triple T's safety and effectiveness in 28 patients, with most achieving normal hormone levels after six months and many discontinuing blood pressure medications. • This innovative treatment could potentially help millions worldwide, as primary aldosteronism affects 1 in 20 people with high blood pressure but is currently underdiagnosed and undertreated.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access